Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prenatal intra-amniotic ER004 for male X-linked hypohidrotic ectodermal dysplasia (XLHED)
2021-002532-23Phase 2Active
- Sponsor
- EspeRare
- Start
- Jul 2021
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of EDI200 in ectodermal dysplasia 15 (HED) and Anhidrotic ectodermal dysplasia (HED) (2 arms), sponsored by EspeRare. Primary endpoint: Pilocarpine-induced sweat volume at 6 months. Started Jul 2021; status: active.
02
Drugs
EDI200
03
Conditions
ectodermal dysplasia 15 (HED)Anhidrotic ectodermal dysplasia (HED)
Beyond the preview
Go deeper on 2021-002532-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002532-23.